Obesity and Related Metabolic Abnormalities during Antipsychotic Drug Administration: Mechanisms, Management and Research Perspectives
The DOI matches its Crossref record.
Abstract
Excessive body weight gain (BWG) is a common side effect of some typical and atypical antipsychotic drugs (APs). Convergent evidence suggests a hierarchy in the magnitude of BWG that may be induced by diverse agents, being very high for clozapine and olanzapine; high for quetiapine, zotepin, chlorpromazine, and thioridazine; moderate for risperidone and sertindole; and low for ziprazidone, amisulpiride, haloperidol, fluphenazine, pimozide, and molindone. BWG may be related to increased appetite that is due to drug interaction with the brain monoaminergic and cholinergic systems and to the metabolic/endocrine effects of hyperprolactinemia. Subjects with schizophrenia and bipolar disorders manifested a significantly high prevalence of diabetes, even before the introduction of atypical APs. However, clozapine and olanzapine appear to display a high propensity to induce glucose dysregulation and dyslipidemia. Sudden BWG, insulin resistance, increased appetite, and related endocrine changes also may be involved in the development of glucose intolerance and dyslipidemia in predisposed individuals. Patients should be informed of these side effects in order to prevent excessive BWG, and their blood glucose and lipids should be monitored before treatment and then at regular intervals. Nutritional advice must be given and regular physical exercise recommended. An appropriate selection of APs ought to be based on drug efficacy for specific patients and assessment of relevant risk factors such as propensity to gain weight; family or personal history of diabetes or hyperlipidemia; and elevated fasting serum glucose, lipid, or insulin levels. At present, there is no standardized pharmacological treatment for AP-induced BWG. Some studies have assessed the effects of agents such as amantadine, orlistat, metformin, nizatidine, and topiramate on AP-induced BWG. Further studies will provide tools to identify patients at high risk for obesity and metabolic abnormalities during AP administration. Excessive body weight gain (BWG), glucose intolerance, and dyslipidemia during treatment with antipsychotic drugs (APs) were reported in the late 1950s [14,101]. However, after 1990, interest in these problems increased noticeably, mainly because of the high propensity of some new atypical APs to induce these side effects (Fig.1). The APs are currently used in diverse mental disorders. Hence, excessive BWG and metabolic dysfunction are not exclusive of subjects with schizophrenia. In the case of bipolar disorders, AP-induced BWG may be additive to that induced by mood stabilizers [14,48,101]. The clinical features [2,14,24,133,139,140] and mechanisms [14,34,68,87,93,101,130] of BWG and metabolic dysfunction have been previously reviewed. In this article, we focus on a unified theory to explain these side effects, based on the interaction of APs with brain neurotransmitters involved in appetite regulation. This review comprises the following sections: 1) the clinical features of AP-induced BWG; 2) the effects of APs on carbohydrate and lipid metabolism in humans and experimental animals; 3) mechanisms involved in BWG, glucose, and lipid dysregulation; 4) strategies for prevention and treatment of these side effects; and 5) research perspectives in the field. The following sources were consulted: MEDLINE, Cochrane database system, and PsychINFO. Numerous articles referred to in leading articles also were consulted. The literature on this subject has increased so rapidly that it was impossible to include all the data recently published. For the first two sections, references that illustrate current controversies in the field were selected.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Metabolic side effects of antipsychotic medication
Tschoner, A., Engl, J., Laimer, M., Kaser, S., Rettenbacher, M., Fleischhacker, W. W., Patsch, J. R., & Ebenbichler, C. F. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01416.x · Cited by 253
The TNF-α System: Functional Aspects in Depression, Narcolepsy and Psychopharmacology
Berthold-Losleben, M., & Himmerich, H. (2008) · Current Neuropharmacology · doi:10.2174/157015908785777238 · Cited by 119
“This might be particularly true for substances such as clozapine that have independent effects on weight regulation and the TNF- system [4, 35].”
BackgroundCardiovascular disease risk among the poor and homeless—what we know so far
Jones, C., Perera, A., Chow, M., Ho, I., Nguyen, J., & Davachi, S. (2009) · Current Cardiology Reviews · doi:10.2174/157340309787048086 · Cited by 94
“Atypical antipsychotics have been associated with weight gain (sometimes in excess of 7 kg), increased insulin concentrations, and insulin resistance [63].”
BackgroundBjörkhem-Bergman, L., Asplund, A. B., & Lindh, J. D. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881109353461 · Cited by 72
Wysokiński, A., & Sobów, T. (2016) · Nordic Journal of Psychiatry · doi:10.3109/08039488.2015.1056225 · Cited by 7
Metadata
- Authors
- Baptista, T., Kin, N. M., Beaulieu, S., & de Baptista, E. A.
- Venue
- Pharmacopsychiatry
- Publisher
- Georg Thieme Verlag KG
- Published
- 2002-11
- Volume
- 35
- Issue
- 6
- Pages
- 205-219
- ISSN
- 0176-3679 (ISSN-L)
- 1439-0795
- OpenAlex
- W1983408983
- Cited by
- 230
- References
- 0
- FWCI
- 10.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Obesity and Related Metabolic Abnormalities during Antipsychotic Drug Administration: Mechanisms, Management and Research Perspectives. https://app.cochat.ai/papers/10.1055/s-2002-36391
- The paper
- Baptista, T., Kin, N. M., Beaulieu, S., & de Baptista, E. A. (2002). Obesity and Related Metabolic Abnormalities during Antipsychotic Drug Administration: Mechanisms, Management and Research Perspectives. Pharmacopsychiatry. https://doi.org/10.1055/s-2002-36391
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.